Amylin Pharmaceuticals (AMLN) Reports Q1 Loss of 24c, Misses by 1c
Tweet
Share
E-mailGet Alerts AMLN Hot Sheet
Price: $30.98 --0%
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
BTTX, VAXX, ELYS, More
Financial Fact:
Collaborative profit sharing: 0
Today's EPS Names:
BTTX, VAXX, ELYS, More
Join SI Premium – FREE
Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) reported Q1 EPS of ($0.24), $0.01 worse than the analyst estimate of ($0.23). Revenue for the quarter came in at $152.7 million versus the consensus estimate of $156.73 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- BJ's Wholesale Club (BJ) Tops Q2 EPS by 19c, Beats on Revenue; Offers FY27 EPS Guidance
- Navios Maritime Partners (NMM) Tops Q2 EPS by 34c
- Deere & Co. (DE) Tops Q3 EPS by 41c, raises guidance
Create E-mail Alert Related Categories
Earnings, Hot EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
